<DOC>
	<DOCNO>NCT01362972</DOCNO>
	<brief_summary>In European Union ( EU ) , plerixafor indicated combination granulocyte colony stimulate factor ( G-CSF ) enhance mobilisation haematopoietic stem cell ( HSCs ) peripheral blood ( PB ) collection subsequent autologous transplantation patient lymphoma multiple myeloma ( MM ) whose cell mobilise poorly . This clinical outcome analysis prospectively define cohort patient data report retrospectively European Group Blood Marrow Transplantation ( EBMT ) lymphoma multiple myeloma ( MM ) , whose cell mobilize poorly , undergone autologous haematopoietic stem cell ( HSC ) transplantation year 2008 include 2012 . The EBMT non-profit , scientific society represent 600 transplant center mainly Europe . The EBMT promote activity aim improve stem cell transplantation cellular therapy , include register activity relate stem cell transplant . Data enter , manage , maintain central database internet access ; EBMT center represent database . The analysis data well establish registry like EBMT registry allow follow large number patient representative patient population receive plerixafor .</brief_summary>
	<brief_title>Analysis Data Collected European Group Blood Marrow Transplantation ( EBMT ) Registry Cohort Patients Receiving Plerixafor</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>For inclusion cohort analysis , patient must data EBMT registry meet follow criterion : Adults diagnose lymphoma multiple myeloma ( MM ) Received first autologous transplant peripheral blood ( PB ) non exvivo manipulate stem cell time period list use cell mobilise one follow regimen : plerixafor plus granulocyte colony stimulate factor ( GCSF ) plerixafor plus GCSF plus chemotherapy GCSF alone GCSF plus chemotherapy Note : Patients include plerixafor group treat accord label Provision inform consent ( i.e. , patient data EBMT registry sign consent time transplantation potential use data analysis ) Patients treat plerixafor NOT accord European Union ( EU ) label . Patients whose graft product underwent ex vivo manipulation exclude analysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>